2. Academic Validation
  3. Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747)

Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) benzamide (ADL5747)

  • J Med Chem. 2009 Sep 24;52(18):5685-702. doi: 10.1021/jm900773n.
Bertrand Le Bourdonnec 1,  Rolf T Windh,  Lara K Leister,  Q Jean Zhou,  Christopher W Ajello,  Minghua Gu,  Guo-Hua Chu,  Paul A Tuthill,  William M Barker,  Michael Koblish,  Daniel D Wiant,  Thomas M Graczyk,  Serge Belanger,  Joel A Cassel,  Marina S Feschenko,  Bernice L Brogdon,  Steven A Smith,  Michael J Derelanko,  Steve Kutz,  Patrick J Little,  Robert N DeHaven,  Diane L DeHaven-Hudkins,  Roland E Dolle
Affiliations

Affiliation

  • 1 Departments of Chemistry, Adolor Corporation, 700 Pennsylvania Drive, Exton, Pennsylvania 19341, USA. blebourdonnec@adolor.com
PMID: 19694468 DOI: 10.1021/jm900773n
Abstract

Selective, nonpeptidic delta Opioid Receptor agonists have been the subject of great interest as potential novel analgesic agents. The discoveries of BW373U86 (1) and SNC80 (2) contributed to the rapid expansion of research in this field. However, poor drug-like properties and low therapeutic indices have prevented clinical evaluation of these agents. Doses of 1 and 2 similar to those required for analgesic activity produce convulsions in rodents and nonhuman primates. Recently, we described a novel series of potent, selective, and orally bioavailable delta Opioid Receptor agonists. The lead derivative, ADL5859 (4), is currently in phase II proof-of-concept studies for the management of pain. Further structure activity relationship exploration has led to the discovery of ADL5747 (36), which is approximately 50-fold more potent than 4 in an animal model of inflammatory pain. On the basis of its favorable efficacy, safety, and pharmacokinetic profile, 36 was selected as a clinical candidate for the treatment of pain.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z